Skip to main content

Table 3 Clinical response and symptomatic remission outcomes in the long-term study among participants who completed dose optimization, by optimized dose (n=327)

From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

 

LDX

30 mg/d (n=44)

50 mg/d (n=112)

70 mg/d (n=171)

All Doses (n=327)

Clinical response, n (%)

42 (95.5)

107 (95.5)

164 (95.9)

313 (95.7a)

Symptomatic remission, n (%)

38 (86.4)

95 (84.8)

145 (84.8)

278 (85.0b)

  1. aSee Figure 4.
  2. bSee Figure 5.
  3. Abbreviation: LDX lisdexamfetamine dimesylate.